Arthritis drug should be removed from market, says consumer groupBMJ 2002; 324 doi: https://doi.org/10.1136/bmj.324.7342.869/a (Published 13 April 2002) Cite this as: BMJ 2002;324:869
- Fred Charatan
In a petition last month to the Food and Drug Administration, Public Citizen, a Washington based consumer watchdog, asked that leflunomide (Arava) be removed from the market.
Leflunomide was first marketed in the United States in September 1998 to treat rheumatoid arthritis. Over the next three years, it was associated with at least 130 cases of severe liver toxicity, including 56 admissions to hospital and 12 deaths, according to FDA data. Two of those who died were in their 20s. …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial